Add BrightSurf on Google Email

Beth Israel Deaconess Medical Center


Videoconferencing between hospital clinicians, nursing home staff offers new dementia treatment

A new study found that video consultation technology brings together nursing home staff and hospital-based clinical experts to manage behavioral challenges associated with dementia. The program, Project ECHO-AGE, resulted in significant reductions in the use of physical restraints and antipsychotic medication among patients.

SourceBeth Israel Deaconess Medical Center·JournalJournal of the American Medical Directors Association·DateJun 6, 2016

Improvements to online health information can help reduce barriers to care for pancreatic cancer

A new study found that online information about pancreatic cancer is often written at a reading level beyond the sixth grade, making it inaccessible to the general population. The research highlights the need for accurate and understandable health information to empower patients in making informed decisions about their care.

SourceBeth Israel Deaconess Medical Center·JournalJAMA Surgery·DateMay 5, 2016

Screening method uncovers drugs that may combat deadly antibiotic-resistant bacteria

Researchers at Beth Israel Deaconess Medical Center have developed a method to identify new antimicrobials that target antibiotic-resistant bacteria. Approximately 10,000 compounds were screened, and three approved drugs showed promise in inhibiting the growth of carbapenem-resistant Enterobacteriaceae (CRE).

SourceBeth Israel Deaconess Medical Center·JournalAssay and Drug Development Technologies·DateApr 29, 2016

Scientists report on novel method for extending the life of implantable devices in situ

Researchers at Beth Israel Deaconess Medical Center report a breakthrough in extending the life of implantable devices by rapidly regenerating molecular constituents in situ. The new approach, using an enzyme called Staphylococcus aureus Sortase A, enables repeated regeneration of bioactive films without device removal.

SourceBeth Israel Deaconess Medical Center·JournalNature Communications·DateApr 13, 2016

New drug candidate is promising therapeutic option for angiogenic retinal diseases

A research team at Beth Israel Deaconess Medical Center has identified a small molecule that prevents the overgrowth of blood vessels in animal models of aged macular degeneration and retinopathy of prematurity. The new findings show that this molecule, named Vasotide, can be delivered in eye drops, offering a promising alternative to ...

SourceBeth Israel Deaconess Medical Center·JournalScience Translational Medicine·DateOct 14, 2015

New clues to the genetic origins of obesity

A study led by Beth Israel Deaconess Medical Center and MIT reveals a genetic circuit controlling fat storage versus burning. The research identifies two key genes, IRX3 and IRX5, which are under the control of the FTO gene variant associated with obesity. Manipulating this pathway may offer a new treatment approach for obesity.

SourceBeth Israel Deaconess Medical Center·JournalNew England Journal of Medicine·DateAug 19, 2015

BIDMC research shows endovascular repair of abdominal aortic aneurysm is safe

Researchers at Beth Israel Deaconess Medical Center found that endovascular aortic repair provides better outcomes, including lower mortality rates and shorter hospital stays, compared to open surgical repair. The study shows improved long-term results over time, with benefits extending up to eight years after surgery.

SourceBeth Israel Deaconess Medical Center·JournalNew England Journal of Medicine·DateJul 23, 2015

Study shows novel HIV vaccine regimen provides robust protection in non-human primates

A new study led by Beth Israel Deaconess Medical Center shows that a novel HIV-1 vaccine regimen provides complete protection against simian immunodeficiency virus in half of vaccinated non-human primates. The vaccine regimen involves a viral vector boosted with a purified envelope protein, demonstrating improved protection over previo...

Single 30-day hospital readmission metric fails to reflect changing risk factors

A new study suggests that the standard 30-day hospital readmission metric fails to accurately reflect changing risk factors. Researchers found that early readmissions (0-7 days post discharge) were associated with acute illness markers, while late readmissions (8-30 days post discharge) were more closely tied to chronic illness burden.

SourceBeth Israel Deaconess Medical Center·JournalAnnals of Internal Medicine·DateJun 2, 2015

How to short circuit hunger

Scientists at Beth Israel Deaconess Medical Center have discovered a long-sought component of the neural network that controls eating, finding that the melanoncortin 4 receptor-regulated circuit inhibits and controls hunger. Activating this circuit reduces feeding in mice and removes feelings of intense hunger.

SourceBeth Israel Deaconess Medical Center·JournalNature Neuroscience·DateApr 27, 2015